Virios Therapeutics Received FDA Feedback On Requirements For Advancing Imc-2 (Combination Of Valacyclovir + Celecoxib) As A Treatment For Fatigue, Orthostatic Intolerance, And Other Symptoms Associated With Long Covid Illness
Virios Therapeutics Received FDA Feedback On Requirements For Advancing Imc-2 (Combination Of Valacyclovir + Celecoxib) As A Treatment For Fatigue, Orthostatic Intolerance, And Other Symptoms Associated With Long Covid Illness
Virios Therapeutics收到了美国食品药品管理局关于推进Imc-2(伐昔洛韦+塞来昔布的组合)作为疲劳、体位不耐受和其他与长期Covid疾病相关的症状的治疗的要求的反馈
Virios Therapeutics Received FDA Feedback On Requirements For Advancing Imc-2 (Combination Of Valacyclovir + Celecoxib) As A Treatment For Fatigue, Orthostatic Intolerance, And Other Symptoms Associated With Long Covid Illness
Virios Therapeutics收到了美国食品药品管理局关于推进Imc-2(伐昔洛韦+塞来昔布的组合)作为疲劳、体位不耐受和其他与长期Covid疾病相关的症状的治疗的要求的反馈